SEC Form 4 · accession 0000899243-19-006182
CRISPR Therapeutics AG · CRSP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Samarth Kulkarni
Officer — Chief Executive Officer · Director
Period of report
Mar 1, 2019
Accepted (ET)
Mar 5, 2019 · 5:57 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001674416
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares | Mar 1, 2019 | F | 748 | $39.97 | D | 166,542 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On December 1, 2017, the reporting person was granted 26,667 restricted stock units. On March 1, 2019, 1,667 restricted stock units vested, and the reporting person forfeited 748 common shares to the issuer to satisfy tax withholding obligations.